Lesko, Lawrence

Polli JE, Lawrence XY, Cook JA, Amidon GL, Borchardt RT, Burnside BA, Burton PS, Chen ML, Conner DP, Faustino PJ, Hawi AA, Hussain AS, Joshi HN, Kwei G, Lee HL, Lesko LJ, Lipper RA, Loper AE, Nerurkar SG, Polli JW, Sanvordeker DR, Taneja R, Uppoor RS, Vattikonda CS, Wilding I, Zhang G. Summary workshop report biopharamceutics classification system—implementation challanges and extention opportunities. J Pharm Sci 2004 93(6) 1375-1381. 

Lawrence. Lesko, Ronald A. Salerno, Brian B. Spear, Donald C. Anderson,... 

Lawrence J. Lesko Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology and Biopharmaceutics, Rockville, Maryland, U.S. 

Shiew-Mei Huang, Lawrence J. Lesko, and Robert Temple... 

Figure 19.2 The reasons why clinical development of drugs are sometimes terminated and the drug does not reach the market are due to safety issues, marketing reasons, lack of efficacy, and/or pharmacokinetics/bioavailability (from Dr Lawrence Lesko, FDA Regulatory Standards BA/BE. PK/PD in Strategies for Oral Drug Delivery, Lake Tahoe, USA, March 6-10, 2000).

---